Specialist distributor Diploma (LON:DPLM) delivered forecast-beating FY26 earnings and revenue thanks to strong organic growth. The firm also published FY27 guidance which it said was ahead of its financial model, although it signalled growth moderating.
Diploma beats raised forecasts
Fot the year to September, Diploma delivered revenue of £1.84 billion, a 21% increase on the previous year. That beat its previous, rasied forecast of a 20% increase in revenue to £1.83 billion.
Organic revenue rose 15%, ahead of its 14% forecast, with product extension supporting ‘structurally stronger growth’. Within the Controls division, which represents 61% of group sales, the firm highlighted the performance of Peerless and Windy City.
Within Seals, which represents 26% of sales, the company flagged a pick-up in H2 with North American demand up by high single digits. In Life Sciences, which makes up 13% of sales, organic growth was just 1% due to tough healthcare markets and short product life cycles.
Operating profit increased 42% to £487, topping the £485 million consensus and resulting in a margin of 26.5%, Adjusted EPS rose 45% to 255.6p, also ahead of the consensus.
Growth to moderate in FY27
For the current financial year, the group expects total revenue growth to slow to around 12%. Organic growth will be around 6%, while acquisitions are expected to add a similar amount, although that will increase with future acquisitions.
Revenue is seen rising by double digits in Q1, then moderating in Q2 as sales lap a very strong prior-year period. Operating margins are seen around 25.5%, slightly lower then the 26.5% recorded in FY26.
A 12% increase in revenue would equate to around £2.06 billion, above the current consensus of £2.01 billion. Similarly, a 25.5% operating margin would equate to profit of £525 million, above the current forecast of £502 million.
‘The new year has started with great momentum’, commented CEO Johnny Thomson. ‘We have a diversified portfolio, attractive end market exposures, a strong acquisition pipeline and brilliant teams. We’re confident in delivering another year of sustainable quality compounding.’
Diploma FY26 results and FY27 guidance (in £ millions)
| FY26 | Growth | FY27 guidance | FY27 consensus | |
| Revenue | 1,840 | +21% | 2,060 | 2,010 |
| Operating profit | 487 | +42% | 525 | 502 |
Source: Company accounts

As CEO Johnny Thomson says, Diploma keeps on delivering sustainable quality compounding of earnings, which is why the market loves it. Not only does it generate reliable organic growth, it has an impressive record of finding earnings-accretive acquisitions and sweating them.
The end markets for Controls and Seals, like aerospace, defence, datacentres, nuclear power and water, are large, attractive and growing. Life Sciences is a tougher market, and H1 2027 is likely to remain challenging, but its long-term prospects are also attractive.
Although it is already above-consensus, we suspect the new FY27 guidance is conservative and the company will upgrade forecasts incrementally as usual. However, even with that caveat, we struggle to get our heads round the share price.
History shows starting valuations matter hugely for long-term returns, and at just under 30 times earnings Diploma is too expensive for us. Despite its obvious quality, we suspect buying the stock here is likely to lock in poor returns for the next 10 years.




